Celularity Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.86 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.38Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $44.8M Enterprise Value $72.4M Shares Outstanding 25.6M diluted Next Earnings Date16 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Celularity Inc. is undergoing a critical strategic pivot to transition from a diversified biomaterials and cellular medicine company into a lean, longevity-focused therapeutics developer. While the company has successfully executed non-dilutive capital transactions—such as the $35 million strategic out-licensing of its biomaterials portfolio to NexGel and a $12.2 million New Jersey NOL sale—it remains severely constrained by liquidity. With only $6.2 million in cash against a $68.4 million working capital deficit at year-end 2025, and a recent Nasdaq non-compliance notice due to delayed Q1 2026 Form 10-Q filing, the stock represents a high-risk, speculative situation. A 'Hold' is recommended pending successful filing of delayed reports and stabilization of the balance sheet. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to file its Q1 10-Q or secure a Nasdaq extension, leading to delisting. Liquidity constraints prevent the execution of clinical trials, and the inability to raise capital forces a curtailment of operations, asset fire sales, or bankruptcy protection under the weight of its working capital deficit. Base CaseCentral scenario The company successfully files its delayed Q1 2026 Form 10-Q, regains Nasdaq compliance, and utilizes the upfront proceeds from the NexGel transaction to extend its runway. Commercialization of cenplacel-L in permissive markets like Florida, supported by the Fountain Life partnership and newly appointed CCO Rick Gonzalez, begins to generate scalable, high-margin revenue. Bull CaseUpside scenario Celularity's successful pivot to a pure-play longevity and cellular medicine company, supported by the $13.3M asset sale to NexGel and the retirement of $13M in debt, provides a cleaner balance sheet. Commercial rollouts of its placenta-derived therapies in Florida under the new investigational-use framework and the upcoming 2026 launch of the Fontaine Vitale facility in Bali with Genting Berhad serve as major catalysts to drive high-margin manufacturing and licensing revenues. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |